Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 12Vincristine 9Etoposide 8venetoclax 6Methotrexate 6Doxorubicin 6Dexamethasone 6Cytarabine 6Prednisone 5Calcium Dobesilate 5prednylidene 4pegaspargase 4merphos 4dexamethasone acetate 4dexamethasone 21-phosphate 4deltacortene 4calaspargase pegol 4auricularum 4Specimen Handling 4Granulocyte Colony-Stimulating Factor 4fludarabine phosphate 3daratumumab 3Thioguanine 3Rituximab 3Peripheral Blood Stem Cell Transplantation 3Mercaptopurine 3Magnetic Resonance Spectroscopy 3Leucovorin 3Hydrocortisone 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Abatacept × 90 days × Clear all
NCT07388563 2026-05-08

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Suspended
20 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡